Nirsevimab: First Approval

Area of Science:

• Immunology
• Virology
• Pediatrics

Background:

• Respiratory Syncytial Virus (RSV) is a leading cause of lower respiratory tract disease in infants.
• Current prevention strategies for RSV disease have limitations.
• There is a need for effective, long-acting preventative measures against RSV.

Purpose of the Study:

• To summarize the development milestones of nirsevimab.
• To highlight the approval of nirsevimab for RSV disease prevention in infants.
• To discuss the significance of nirsevimab as a single-dose preventative therapy.

Main Methods:

• Development of a long-acting intramuscular monoclonal antibody targeting the RSV F protein.
• Modification of the antibody's Fc region to extend serum half-life.
• Clinical development and regulatory review for infant protection.

Main Results:

• Nirsevimab demonstrated an extended serum half-life, enabling single-dose administration.
• Nirsevimab received approval in the EU and UK for preventing RSV lower respiratory tract disease.
• The therapy is indicated for neonates and infants during their first RSV season.

Conclusions:

• Nirsevimab represents a significant advancement in RSV disease prevention.
• The single-dose regimen simplifies administration and ensures season-long protection.
• Nirsevimab offers a new option for protecting vulnerable infant populations from RSV.